ARTICLE | Clinical News

Virulizin update

October 17, 1994 7:00 AM UTC

IMUTF will delay for three months its Phase III trial in pancreatic cancer and a Phase I/II trial in AIDS, and is recalling product already in the field, after recently tested lots failed to meet the potency specifications of an assay used for quality control.

In addition to the trial, the recalled agent had been released for compassionate use. ...